1/10 Welcome to #TenPostNephJC Can we move beyond slowing CKD → to actually repairing the kidney? Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.

Hi everyone! Pallavi from New Delhi. No COI #NephJC Using flozins occasionally in transplants-mostly in those with proteinuria+-PTDM.

moving on from IgAN to FSGS: BI 764198 a TRPC6 inhibitor reduces proteinuria in an N = 67 phase 2 RCT www.thelancet.com/journals/lan... in @thelancet.com #NephSky

Editors’ Choice 2025: Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial This phase 2 trial tested ravulizumab, a complement C5 inhibitor, in adults with IgA nephropathy. Check out the paper here: kidney.pub/JASN0534

Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease #VisualAbstract by Augusto Cesar S Santos Jr https://www.kireports.org/article/S2468-0249(25)00774-0/fulltext#SGLT2i#Cardiorenal#Nonalbuminuric#VisualAbstractwhuang0824

1/10 Last #NephJC we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN #TenPostNephJC Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit. www.nejm.org/doi/full/10....

Hi everyone! Pallavi from New Delhi. No COI #NephJC

Check out the VA for VALIANT from @nephromommy-akshu.bsky.social #NephJC www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract

The LIBERATE-D VA by @sejalplakhani.bsky.social Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky www.nephjc.com/news/liberateva

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇 www.nejm.org/doi/10....#NephJC

T3f: #NephJC Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA). Do you think either has the advantage?

T0k: #NephJC The 96-week extension demonstrated durability: ⬇️proteinuria fell 52% ⬇️Gd-IgA1 dropped 66% ⬇️hematuria declined 75% ⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m² ⚠️Safety: mild injection-site reactions and transient infections pubmed.ncbi.nlm.nih....#NephJC

Hi everyone! Pallavi from New Delhi ! The day light saving change in #NephJC doesn't help when in India - approaching time to leave for work..will be lurking . Excited about targeted therapeutic approaches in IgAN . No COI.

Day light saving always confuses me. One hour early for #NephJC 🥲 and wondering where everyone else is! 😂

Check out the awesome visual abstract by @salinesolut.bsky.social Attacking the origins of IgAN with atacicept ⚔️ www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract

APRIL/BAFF inhibition: 🎯💊🩺 Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression. #NephJC

BTW super interesting basket trial from India (Ongoing) bsky.app/profile/hswa... Maybe they can eventually add a povetacicept arm 😏 #NephJC

Treatment Approach: 💊 Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach. a) Generic responses to HTN/proteinuria b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC

Let’s recapitulate the history and evidence-based developments of IgA Nephropathy. We’ve known about the pathologic etiology for decades, however there was a huge therapeutic plateau until quite recently. 💉💊 In the last few years, new therapies are coming up rapidly. #NephJC

The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky ✍️Summary by @thekidneywhisperer.bsky.social and @glomerican.bsky.social www.nephjc.com/news/igan-kd...

⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline 🎨 Nice visual summary by @roxnonna23.bsky.social www.nephjc.com/news/2025/10...

Apart from myeloma and MGRS , what other diseases should we think of in case of increased UPCR with no albumunuria in urine analysis. Urine alb- trace UPCR-5.2 SIFE,SFLC - normal @askrenal.bsky.social #askrenal #Nephsky

1/10 Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC . Read the article 👇 pubmed.ncbi.nlm.nih....#NephJC

⏰30 min before the #NephJC chat Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.

Hello everyone! Pallavi here from New Delhi. No COI. #NephJC

www.nejm.org/doi/full/10.... There’s some trial data on prevention of albuminuria #nephjc

T2l Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two! What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC www.thelancet.com/jo...#NephJC

Check out the insightful VA that makes sense of the updates 🧠 #nephjc VA by @sejalplakhani.bsky.social

Hi everyone! Pallavi from New Delhi. no COI. #NephJc

Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC Infographic by @nephroseeker.medsky.socia

Hi everyone! Pallavi from New Delhi, joining #Nephjc after a long hiatus. lurking today .. No COI.

The #NephJC editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions ✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads www.nephjc.com/news/nephjc-... #MedSky #NephSky

Hi everyone! Good morning from Kerala, God's own country. will be lurking today. COI: flozinator >> RAASblocker

From Rivka Galchen’s article in @newyorker.com: “The kidney, a tremendously under-celebrated organ, basically does four-dimensional sudoku with ions.” And that’s how I’m going to explain it from now on.

Hilarious (and sobering) essay on the use of AI in medical research & manuscript writing Read the whole thing! John Daugirdas has been on the cutting edge of tech in meded before #MedEd was thing onlinelibrary.wiley.com/doi/10.1111/... #MedSky #NephSky

1/10 Last #NephJC we discussed the role of prophylactic DDAVP for preventing post kidney biopsy (KBx) bleed #TenPostNephJC . The articles 👇 @kireports.bsky.social @asnpublications.bsky.social @jeyakumarmeyyappan.bsky.social www.kireports.org/article/S246... pubmed.ncbi.nlm.nih.gov/40067357/

Again in the haemostasiology world, we do not favour the use of bleeding times. The trend is toward viscoelastic methods and thrombin generation assays. These need to be studied in nephrology too. #NephJC

Don´t forget to advocate the resolution led by Guatemala on #WHA78: 🌍 Chronic kidney disease affects over 850M We must shift from silent neglect to strategic action. Awareness, prevention, and equity in care are our next steps. #NephJC @theisn.org #NephSky #MedSky www.thelancet.com/jo...

Hi everyone! Pallavi from New Delhi. No COI. Have used desmopressin for high risk patients #Nephjc

Alright #PedNeph #NephTwitter ⁦‪#NephJC What do you think? Truly a comparative effectiveness trial? Tacrolimus or Mycophenolate Mofetil for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial jamanetwork.com/journals/jam...

1/10 We were delighted to discuss the first ever @KDIGO ADPKD guidelines this March! So satisfied with the chat itself that we forgot to post the #TenPostsNephJC 😉 So here we are! Better late than never.#NephJC kdigo.org/guidelines/a...

We are pleased to announce the publication of the KDIGO 2025 Guideline for Nephrotic Syndrome in Children—an update to Chapter 4 of the KDIGO 2021 Glomerular Diseases Guideline. 📄 Read in @kidneyint.bsky.social: kdigo.co/Nephrotic-Sy... 🧵More below ⬇️

Nephro-pharmacists like Wendy St Peter are trying very hard to educate across disciplines with their learning collaborative AKHOMM (dont think theyre on bluesky but will let them know!) www.kidneymedicationmanagement.org pubmed.ncbi.nlm.nih.gov/39552516/

T3c: #nephjc 🔸7% survival boost with continued metformin in CKD4+ challenges current restrictions 🔸Benefit persists despite observational design, bolstered by rigorous target-trial methods 🔸Aligns with prior data showing glycemic deterioration post-discontinuation

T0i: #NephJC Evidence supporting strict metformin discontinuation in CKD is limited. MALA risk it’s the "acid-ental perfect storm" made by pH and low eGFR. It often occurs with acute stressors like heart failure, sepsis, shock, or AKI, which can happen at any GFR

Hi everyone! Late to #NephJC and lurking today despite being really interested in this topic. Recovering from a bad viral 🤕. No COI.

Hey #NephSky & #MedSky 9pm EST 4/15/25, only on #Bluesky Discussion on the use of metformin in advanced CKD. Worried about lactic acidosis 💪?! What's the evidence that an eGFR < 30 ml/min is the ideal cutoff ✂️? Are there benefits to continuing 💊 www.nephjc.com/news/metformin-tte

Hey #NephSky and #MedSky Check out the VA for our discussion 4/15/25 at 9pm EST Metformin-Should I Stay or Should I Go (in patients with advanced CKD) VA by @nephroseeker.medsky.social www.nephjc.com/news/metformin-ckd-va